These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6750029)

  • 21. Detection and quantitation of cannabinoids in biological fluids: specificity and kinetics after smoking.
    Scherrmann JM; Hoellinger H; Nguyen-Hoang-Nam ; Boudet L; Pichon J; Do-Cao-Thang
    Clin Toxicol; 1981 May; 18(5):565-71. PubMed ID: 6268351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EMIT cannabinoid assay: confirmation by RIA and GC/MS.
    O'Connor JE; Rejent TA
    J Anal Toxicol; 1981; 5(4):168-73. PubMed ID: 7024638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cannabinoid intake by passive smoking].
    Magerl H; Wiegand C; Schulz E
    Arch Kriminol; 1987; 179(1-2):31-7. PubMed ID: 3551865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Further observations: false negative EMIT cannabinoids.
    Joern WA
    J Anal Toxicol; 1989; 13(2):126. PubMed ID: 2659892
    [No Abstract]   [Full Text] [Related]  

  • 25. Incidence of cannabinoids in medical examiner urine specimens.
    Isenschmid DS; Caplan YH
    J Forensic Sci; 1988 Nov; 33(6):1421-31. PubMed ID: 3060558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced chemiluminescent enzyme immunoassay for cannabinoids in urine.
    Sharma JD; Aherne GW; Marks V
    Analyst; 1989 Oct; 114(10):1279-82. PubMed ID: 2694864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adolescent marijuana use: concordance between questionnaire and immunoassay for cannabinoid metabolites.
    Silber TJ; Getson P; Ridley S; Iosefsohn M; Hicks JM
    J Pediatr; 1987 Aug; 111(2):299-302. PubMed ID: 3302194
    [No Abstract]   [Full Text] [Related]  

  • 28. Urine testing for marihuana use.
    McBay AJ; Dubowski KM; Finkle BS
    JAMA; 1983 Feb; 249(7):881. PubMed ID: 6337273
    [No Abstract]   [Full Text] [Related]  

  • 29. Lowering the federally mandated cannabinoid immunoassay cutoff increases true-positive results.
    Huestis MA; Mitchell JM; Cone EJ
    Clin Chem; 1994 May; 40(5):729-33. PubMed ID: 8174244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Laboratory detection of marijuana use.
    Schwartz RH; Hawks RL
    JAMA; 1985 Aug; 254(6):788-92. PubMed ID: 2989570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlations on radioimmunoassay, fluorescence polarization immunoassay, and enzyme immunoassay of cannabis metabolites with gas chromatography/mass spectrometry analysis of 11-nor-delta 9-tetrahydrocannabinol-9-carboxylic acid in urine specimens.
    Weaver ML; Gan BK; Allen E; Baugh LD; Liao FY; Liu RH; Langner JG; Walia AS; Cook LF
    Forensic Sci Int; 1991; 49(1):43-56. PubMed ID: 1851715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Presence of inhibitors to the EMIT test in postmortem urine samples.
    Taylor J
    J Forensic Sci; 1989 Sep; 34(5):1055-6. PubMed ID: 2681524
    [No Abstract]   [Full Text] [Related]  

  • 33. Evaluation of immunoassays for cannabinoids in urine.
    Irving J; Leeb B; Foltz RL; Cook CE; Bursey JT; Willette RE
    J Anal Toxicol; 1984; 8(4):192-6. PubMed ID: 6471820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance of immunoassays in screening for opiates, cannabinoids and amphetamines in post-mortem blood.
    Hino Y; Ojanperä I; Rasanen I; Vuori E
    Forensic Sci Int; 2003 Jan; 131(2-3):148-55. PubMed ID: 12590054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A discussion of EMIT d.a.u. assays.
    Gorsky JE
    J Anal Toxicol; 1988; 12(5):300. PubMed ID: 3066996
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparative results with five cannabinoid immunoassay systems at the screening threshold of 100 micrograms/L.
    Wells DJ; Barnhill MT
    Clin Chem; 1989 Nov; 35(11):2241-3. PubMed ID: 2582623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The analysis of cannabinoids in biological fluids.
    NIDA Res Monogr; 1982; 42():1-137. PubMed ID: 6817138
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of six cannabinoid metabolite assays.
    Frederick DL; Green J; Fowler MW
    J Anal Toxicol; 1985; 9(3):116-20. PubMed ID: 3892161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urinary cannabinoids in monitoring abstinence in a drug abuse treatment program.
    Schwartz RH; Willette RE; Hayden GF; Bogema S; Thorne MM; Hicks J
    Arch Pathol Lab Med; 1987 Aug; 111(8):708-11. PubMed ID: 3307687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reducing false-negative tests in urinary drugs-of-abuse screening.
    Luceri F; Godi F; Messeri G
    J Anal Toxicol; 1997; 21(3):244-5. PubMed ID: 9171214
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.